|
Sep 27
|
Vivani Medical obtains Australian approval to begin GLP-1 implant trial
|
|
Sep 26
|
Vivani Medical to Test Implant in Obese and Overweight Patients
|
|
Sep 26
|
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
|
|
Sep 26
|
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
|
|
Sep 24
|
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
|
|
Sep 23
|
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
|
|
Jun 13
|
Vivani Medical Receives FDA Clearance for Trial of Type-2 Diabetes Mini-Implant
|
|
Jun 13
|
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's IND Gains FDA Clearance For Clinical Use (UPDATED)
|
|
Jun 13
|
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
|
|
May 28
|
EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use
|
|
May 28
|
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
|
|
May 13
|
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 9
|
Vivani Medical to Present at TIDES Conference 2024
|
|
Mar 27
|
Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 26
|
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 6
|
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
|
|
Dec 24
|
Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 1.2% More Shares
|